Library

By pinki shah / May 14, 2022

Displaying 1,151 - 1,175 of 2,995

State of the Art Management of Sickle Cell Anemia

State of the Art Management of Sickle Cell Anemia

By: Oyebimpe Adesina, MD

Anticoagulation in the Oncology Patient

Anticoagulation in the Oncology Patient

By: Pamela Dudkiewicz, ARPN

MDS: State of the Art

MDS: State of the Art

By: Paul Koller, MD

Myelodysplasia: Biomarkers, Risk Assessment and Novel Treatments

Myelodysplasia: Biomarkers, Risk Assessment and Novel Treatments

By: Rami Komrokji, MD

Hematology Session I

Hematology Session I

By: Rami Komrokji, Mohamed Kharfan-Dabaja, Guillermo Garcia-Manero

Hematology Session II

Hematology Session II

By: Sikander Ailawadhi, Javier Pinilla-Ibarz, Lisa Welsh

Waldenstrom’s Macroglobulinemia

Waldenstrom’s Macroglobulinemia

By: Steven P. Treon, MD, PhD, ,FACP, FRCP

Waldenstrom’s Macroglobulinemia

Waldenstrom’s Macroglobulinemia

By: Steven P. Treon, MD, PhD, ,FACP, FRCP

Sequencing of Therapies for Multiple Myeloma

Sequencing of Therapies for Multiple Myeloma

By: Tom Martin, MD

Management of Immune Related Adverse Events

Management of Immune Related Adverse Events

By: Alicia Rigby, AOCNP

Management of Immune Related Adverse Events

Management of Immune Related Adverse Events

By: Alicia Rigby, RN, MSN, FNP, AOCNP

Management of Immune Related Adverse Events

Management of Immune Related Adverse Events

By: Alicia Rigby, RN, MSN, FNP, AOCNP

Advances in Immunotherapy

Advances in Immunotherapy

By: Arta M Monjazeb - MD - PhD

Systemic Immunotherapy Combinations

Systemic Immunotherapy Combinations

By: Arta M Monjazeb, MD, PhD

Advances in Immunotherapy

Advances in Immunotherapy

By: Arta M. Monjazeb, MD, PhD

Immunotherapy in Non-Melanoma Skin Cancers (BCC, Squamous & Merkel) and What After IO Failure?

Immunotherapy in Non-Melanoma Skin Cancers (BCC, Squamous & Merkel) and What After IO Failure?

By: Belisario Arango, MD

Immunotherapy in Non-Melanoma Skin Cancers (BCC, Squamous & Merkel) and What After IO Failure?

Immunotherapy in Non-Melanoma Skin Cancers (BCC, Squamous & Merkel) and What After IO Failure?

By: Belisario Arango, MD

Overcoming T-Cell Exhaustion

Overcoming T-Cell Exhaustion

By: Brian S. Henick, MD

Overcoming T-Cell Exhaustion

Overcoming T-Cell Exhaustion

By: Brian S. Henick, MD

New Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue?

New Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue?

By: Bruna Pellini, MD

New Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue?

New Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue?

By: Bruna Pellini, MD

Combined Angio-CT system – Precision therapy in IO

Combined Angio-CT system – Precision therapy in IO

By: Bruno Odisio, MD

Precision Imaging in IO

Precision Imaging in IO

By: Chiara Floridi, MD

Novel Frontiers in the Use of ctDNA in Oncology

Novel Frontiers in the Use of ctDNA in Oncology

By: Christian Rolfo, MD, PhD, MBA, Dr.hc

Biomarkers for Perioperative Immunotherapy?

Biomarkers for Perioperative Immunotherapy?

By: David Carbone, MD